Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer

This study has been completed.
Information provided by (Responsible Party):
North Eastern Germany Society of Gynaecologic Oncology Identifier:
First received: September 9, 2005
Last updated: December 13, 2016
Last verified: December 2016
Compatibility of the topotecan therapy in combination with carboplatin.

Condition Intervention Phase
Ovarian Cancer
Drug: Hycamtin
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multicenter, Prospective Phase-I/II-study: Topotecan and Carboplatin in the Therapy of Patients With Relapsed Ovarian Cancer

Resource links provided by NLM:

Further study details as provided by North Eastern Germany Society of Gynaecologic Oncology:

Primary Outcome Measures:
  • Toxicity [ Time Frame: after each cycle for up to one year ]
    hematological adverse events and non-hematological adverse events grade 3/4

Secondary Outcome Measures:
  • Progression-free Survival [ Time Frame: after every third cycle, for up to one year ]
    progression-free survival according to kaplan-meier-estimator

Enrollment: 28
Study Start Date: June 2004
Study Completion Date: September 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Hycamtin Drug: Hycamtin
Topotecan: 1,0 mg/m²/d, day 1-3; q21d Carboplatin: AUC 5 on day 3 after Topotecan, q21d


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age >= 18 years
  • patient with ovarian cancer after primary therapy
  • bone marrow function leukocytes >= 4,0 x 109/ l, platelets >= 100 109/l, hemoglobin >= 9 g/dl
  • renal function creatinin <= 1,5 mg% or creatinin clearance >= 60 ml/min
  • liver function bilirubin <= 2,0 mg/dl, SGOT, SGPT and AP within 3 fold of the reference laboratory's normal range
  • ECOG <= 2
  • Intention of regular follow-up visits for the duration of the study
  • written informed consent

Exclusion Criteria:

  • any known hypersensitivity against topotecan isomerase-I-inhibitor other medication included in the study protocol
  • ECOG > 2
  • patients with radiotherapy within the last 4 weeks
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00170625

Sponsors and Collaborators
North Eastern Germany Society of Gynaecologic Oncology
Principal Investigator: Jalid Sehouli Charite University, Berlin, Germany
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: North Eastern Germany Society of Gynaecologic Oncology Identifier: NCT00170625     History of Changes
Other Study ID Numbers: 310300
Study First Received: September 9, 2005
Results First Received: October 4, 2016
Last Updated: December 13, 2016
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by North Eastern Germany Society of Gynaecologic Oncology:

Additional relevant MeSH terms:
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Antineoplastic Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017